Viewing nowCombinationEsreptin M Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Withus Pharma Co., Ltd.

MFDS item code 202200906 · Approved 2022.03.02 · Insurance code 660703820
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used together with dietary and exercise therapies to help control blood sugar levels in patients with type 2 diabetes. It can be used alone for patients who are initiating blood sugar control or as an alternative when metformin or sitagliptin monotherapy is insufficient. Additionally, it can be administered in combination with metformin, sulfonylurea, thiazolidinedione, or insulin to improve blood sugar management when control is difficult. It is effective in enhancing blood sugar control through various therapeutic methods.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medicine should be based on the patient’s current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with diabetes drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see section 2, “Patients who must not receive this medicine,” under Precautions for Use). 2. Patients treated with metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may begin with their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see section 5, “General precautions,” under Precautions for Use). No studies have evaluated the safety and efficacy of switching patients previously treated with another oral glucose-lowering agent to this medicine. Any change in treatment for type 2 diabetes may affect glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 2, “Patients who must not receive this medicine,” under Precautions for Use).
This drug is an antidiabetic medication containing sitagliptin and metformin components. First, the sitagliptin component may rarely cause serious allergic reactions. These reactions may include anaphylaxis, angioedema, severe rashes or exfoliative skin disorders; if any of these symptoms occur, the medication should be stopped immediately and a doctor should be consulted. Moreover, sitagliptin can cause acute pancreatitis, which is inflammation of the pancreas; if symptoms such as abdominal pain, nausea, or vomiting occur, immediate medical attention should be sought. The metformin component can cause a rare but life-threatening metabolic disorder known as severe lactic acidosis. Symptoms may include muscle pain, weakness, difficulty breathing, and abdominal pain; if these symptoms occur, the medication should be stopped immediately and the patient should go to the hospital. This drug should not be administered to patients with moderate to severe kidney dysfunction, acute heart disease, heart failure, serious infections, dehydration, liver dysfunction, or to pregnant or breastfeeding women. Additionally, if surgery is planned or if undergoing a radiological iodine contrast examination, the use of this medication should be suspended for a certain period, and it should be restarted only after kidney function is confirmed to be normal. Patients taking this drug should have regular kidney function tests, particularly elderly patients or those with slight kidney impairment should be more careful. Irregular meals, malnutrition, excessive exercise, or concomitant use of other glucose-lowering agents or alcohol may increase the risk of hypoglycemia and should be monitored closely. Side effects such as diarrhea, nausea, vomiting, abdominal pain, headache, upper respiratory infection may occur, and hypoglycemic symptoms may also arise. Signs of hypoglycemia include dizziness, shaking, cold sweat, and if any of these symptoms occur, sweet substances should be consumed immediately. Rarely, severe arthralgia, skin rashes, or blistering skin diseases may occur, and if any of these symptoms occur, a doctor should be consulted. The safety of this drug during pregnancy and breastfeeding has not been established, and it is not recommended for use in children under 18, as safety and efficacy have not been confirmed. In the case of overdose, immediate medical attention should be sought for appropriate treatment, and blood dialysis may be necessary to remove the drug. Finally, the risk of lactic acidosis increases when this drug is taken with alcohol, so avoiding alcoholic beverages is important. During treatment with this drug, regular blood glucose tests and kidney function tests should be performed, and if any abnormal symptoms occur, prompt notification to healthcare personnel is essential.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent air or moisture from entering, and it should be kept at room temperature between 1 degree and 30 degrees. Proper storage preserves the effectiveness of the medication and prevents degradation.
Pink oval film-coated tablets
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Withus Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.